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Purpose: To examine the frequency of computed tomography (CT)-guided biopsy sampling 
errors in chondrosarcomas, as well as the impact of these errors and the achieved surgical margins 
on local recurrence-free survival (LRFS) and disease-specific survival (DSS).
Material and methods: A total of 68 consecutive patients treated for chondrosarcoma from 
2000–2015 were retrospectively reviewed with a minimum follow-up duration of 2 years.
Results: The primary location was at the extremities in 46 patients (67.6%) and at the axial 
skeleton in 22 patients (32.4%). Seven patients underwent planned intralesional curettage. 
Surgical margins were assessed in the remaining 53 patients and included 21 wide (39.6%), 25 
marginal (47.1%), and seven intralesional (13.2%) resections. Biopsy sampling errors occurred 
in ten patients (14.7%). LRFS was 82.2±7.8% at 5 years and 76.9±7.8% at 10 years. An intact 
anatomical barrier was associated with the most preferable LRFS of 89±10.5% after 10 years. 
DSS was 79.2±8.5% at 5 years and 75.5±6.4% at 10 years. The metric distance of the surgical 
margin and the presence of a biopsy sampling error did not affect either LRFS or DSS.
Conclusion: Even though histological grading in chondrosarcoma is difficult, sampling errors 
in preoperative biopsies are relatively rare and do not adversely affect outcomes. The presence 
of an anatomical barrier has a greater impact on LRFS than the metric distance of the surgical 
margins.
Keywords: bone tumor, chondrosarcoma, survival, local recurrence, surgical margin, biopsy 
sampling error
Introduction
Chondrosarcoma is the most common malignant bone tumor in the elderly with an 
estimated incidence of one in 200,000 per year.1 A spectrum of histological subtypes 
demonstrating various clinical behaviors has been identified, ranging from low-grade to 
high-grade and dedifferentiated chondrosarcoma. This primary bone tumor can affect any 
part of the skeleton, but it is mainly located at the pelvis, femur, and proximal humerus.2,3
Although preoperative histological grading has been associated with a high inter- 
and intra-rater variability in cartilaginous tumors, imaging-guided biopsy remains the 
standard diagnostic procedure in chondrosarcoma.4–7 In combination with clinical and 
radiological diagnostics, it primarily directs therapeutic decision-making. Complete 
surgical resection remains the gold standard of treatment since chemotherapy and 
radiation therapy are not effective.8 Different surgical treatments exist, from intral-
esional curettage in low-grade appendicular tumors to wide resection and complex 
bone reconstruction.9,10
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Accurate preoperative grading is highly desired to select 
the most appropriate surgical therapy and to avoid under- or 
over-treatment. However, the definitive histological grading 
of the resected tumor can differ from that of the preopera-
tive biopsy sample; this is referred to as a biopsy sampling 
error in the literature. Such errors are reported to occur in up 
to 41% of cases, with a reported higher incidence in pelvic 
tumors.11 The impact of biopsy sampling errors on disease-
specific survival (DSS) and local recurrence-free survival 
(LRFS) has not yet been studied,11,12 despite previous reports 
of numerous risk factors for LRFS and DSS including histo-
logical grade, anatomical location, tumor volume, sex, age 
or surgical margins.13–16
In recent years, advances in surgical techniques that allow 
more sophisticated limb-sparing reconstructions have led to 
less morbidity and better functional results without compro-
mising DSS or LRFS.17–20 Achieving complete resection with 
tumor-free margins has become challenging considering this 
development. However, the impact of metric measures or the 
quality of the surgical margins (such as biological barriers: 
fascia, periosteum) on LRFS and DSS remain unclear since 
various classifications exist.21,22
Overall, the clinical role of biopsy sampling errors and 
surgical margins has been scarcely reported in chondrosar-
coma. Therefore, the purpose of the current study was to 
examine the frequency of computed tomography (CT)-guided 
biopsy sampling errors in chondrosarcomas, as well as the 
impact of these errors and the achieved surgical margins on 
DSS and LRFS.
Ethics
The study was approved by our local ethics advisory board 
(Kantonale Ethikkommission, Kanton Zürich; registration 
number: 2017 – 01666). Written informed consent was 
obtained from all patients.
Methods
Seventy consecutive patients treated for chondrosarcoma 
from 2000–2015 at a single sarcoma center were retro-
spectively reviewed. Inclusion criteria included a biopsy-
confirmed chondrosarcoma, minimum follow-up of 2 years, 
and provision of written informed consent.
Patient data were retrieved from the electronic medical 
record system. Patient charts were reviewed for demographic 
data, tumor localization, tumor size, type of surgery, radio- or 
chemotherapy, recurrence, and survival.
The primary outcomes of the study were DSS and LRFS 
after 5 and 10 years. DSS was calculated from the date of 
surgery to the date of death from disease. LRFS was calcu-
lated from the date of surgery to the date when local recur-
rence occurred. Clinical and histopathological factors were 
analyzed for their effect on DSS and LRFS.
Histopathology reports were reviewed for histological 
diagnosis (in accordance with WHO guidelines 2013)23 and 
surgical margins. Surgical margins were classified in accor-
dance with Enneking et al.24 The surgical margin in mm and 
the presence of a biological barrier (such as fascia, perios-
teum, corticalis) at the closest resection margin were recorded 
from histopathological reports. Planned intralesional curet-
tage of appendicular low-grade tumors was excluded from 
the analysis of surgical margins. A biopsy sampling error was 
recorded when the histopathological report of the definitive 
resection revealed a different histological grade compared 
with the preoperative biopsy. Metastatic disease at diagnosis 
or systemic progression was defined when histologically 
confirmed metastasis or suspected radiological lesions were 
present with progression within 3 months of follow-up. 
Tumor volume was calculated in cm3 based on magnetic 
resonance imaging (MRI), in accordance with the following 
formula: volume = (A × B × C) / 2; A=cranio-caudal diameter, 
B=medio-lateral diameter, C=antero-posterior diameter.25
Follow-up was conducted at 3-month intervals for the 
initial 2 years, followed by 6-month intervals for another 
3 years, and later annually. For the surveillance of systemic 
progression, chest CT was performed. Imaging of the local 
tumor site was performed using plain radiographs and MRI.
statistics
Statistical analysis was performed using Stata (Release 14; 
StataCorp LP, College Station, TX, USA). Kaplan–Meier 
survival curves were used to estimate event-free survival. 
Categorical factor differences were tested using the log-rank 
test for univariate analysis. The effects of interval scaled 
variables were tested using a univariate Cox proportional 
hazards model. P-values were Bonferroni-corrected to com-
pensate for an increase in probability for a type I error. Factors 
with a significant influence were subsequently included in 
a multivariate Cox proportional hazards model. The level of 
significance for all tests was set at α=0.05.
Results
Patient characteristics
Seventy consecutive patients were treated for biopsy-con-
firmed chondrosarcoma from 2000–2015. All patients were 
treated by three board-certified, fellowship-trained orthope-
dic onco-surgeons at our institute. Two patients were lost to 
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follow-up as they moved abroad. A total of 68 patients were 
available for analysis with a mean follow-up of 5 years (range: 
2–15 years). The demographic data of the included patients 
and tumor characteristics are listed in Table 1. A total of 31 
chondrosarcomas (45.6%) were diagnosed in male patients. 
The mean patient age was 49 years (range: 13–85 years). The 
histological subtype was low-grade in 48.5% of cases (n=33), 
high-grade in 25% (n=17), dedifferentiated in 14.7% (n=10), 
mesenchymal in 2.9% (n=2), clear cell in 1.5% (n=1), myxoid 
extraskeletal in 3.4% (n=3), and secondary chondrosarcoma 
in multiple cartilaginous exostoses in 2.9% of cases (n=2). 
The predominant anatomical site was the proximal femur in 
23 patients (33.8%), followed by the pelvis in 15 patients 
(22.1%). The mean tumor volume was 162.6±352.9 cm3.
Treatment
All patients were reviewed by a multidisciplinary sarcoma 
board prior to surgery. Surgical treatment was performed in 
a total of 60 patients and included limb-sparing surgery in 
55 patients (91.7%), resection and biological reconstruction 
with allograft or autograft in 31 patients (51.7%), implanta-
tion of a modular tumor prosthesis in 17 patients (28.3%), 
and planned intralesional curettage in seven patients (11.7%). 
All patients who were treated using planned intralesional 
curettage were alive at the latest follow-up and no local 
recurrence occurred. An amputation was performed in five 
patients (8.3%) (Table 2). Eight patients did not undergo 
surgery (11.7%). In four of those patients (5.9%) watchful 
Table 1 Patient characteristics and tumor information
Total N=68 (100%)
Follow-up (years) 5 (range: 2–15)
age at diagnosis (years) 49 (range: 13–85)
sex
•	 Male
•	 Female
31 (45.6%)
37 (54.4%)
histological grade
•	 low-grade
•	 high-grade
•	 Dedifferentiated
•	 Mesenchymal
•	 Clear cell
•	 Myxoid extraskeletal
•	 secondary
33 (48.5%)
17 (25.0%)
10 (14.7%)
2 (2.9%)
1 (1.5%)
3 (3.4%)
2 (2.9%)
stage of disease
•	 localized
•	 Metastatic
62 (91.2%)
6 (8.8%)
Tumor localization
•	 appendicular skeleton
•	 axial skeleton
46 (67.6%)
22 (32.4%)
Tumor volume (cm3) 162.6±352.9 (sD)
waiting was preferred in the presence of an asymptomatic, 
appendicular low-grade chondrosarcoma. Primary palliative 
chemotherapy was the first-line treatment for four patients 
(5.9%) in the presence of metastatic disease at the time of 
diagnosis.
Adjuvant radiotherapy was conducted in five patients 
(7.4%) based on the consensus of the multidisciplinary 
sarcoma board (Table 1). The reasons were the presence of 
a high-grade or dedifferentiated lesion with marginal resec-
tion (≤1 mm without a biological barrier) (n=2), a planned 
intralesional resection at the spine or pelvis (n=2), and one 
unplanned intralesional resection of a mesenchymal chon-
drosarcoma of the mandibula.
Biopsy sampling error
A biopsy sampling error occurred in a total of ten patients 
(14.7%). The tumor was located at the axial skeleton in two 
patients and at the appendicular skeleton in eight patients. In 
four patients with a low-grade lesion according to the preop-
erative biopsy, a high-grade lesion was found in the definitive 
histopathological assessment after surgical resection. In three 
patients with a high-grade lesion and one patient with a low-
grade lesion according to the preoperative biopsy, a dediffer-
entiated portion was found in the definitive histopathological 
assessment of the resected specimen. Two patients had a 
chondrogenous neoplasm of unclear malignancy according 
to the preoperative biopsy and a low-grade chondrosarcoma 
was present in the definitive histological assessment. The 
low-grade malignant part of the lesion could not be detected 
despite repeated CT-guided biopsy. The tumors were local-
ized around the knee and the shoulder joint, respectively. A 
secondary resection was necessary in both cases to provide 
adequate treatment. Consequently, sufficient resection could 
be obtained. In the remaining patients in whom a biopsy 
Table 2 Treatment overview for biopsy-confirmed 
chondrosarcoma (n=68)
Intervention N=68 (100%)
Type of surgery
•	 limb-sparing surgerya

	 Resection and biological reconstructiona

	 Tumor prosthesisa

	 intralesional curettagea
•	 amputationa
•	 no surgery
55 (91.7%)
31 (51.7%)
17 (28.3%)
7 (11.7%)
5 (8.3%)
8 (11.7%)
Chemotherapy
•	 Palliative 4 (5.9%)
Radiotherapy
•	 adjuvant 5 (7.4%)
Note: aPercentages apply to 60 patients (=100%) who underwent surgery.
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sampling error occurred, neither changes in decision-making 
nor revision surgeries were necessary.
surgical margins
Surgical margins were assessed in 53 patients in accordance 
with Enneking et al,24 and included: 21 wide (39.6%), 25 
marginal (47.1%), and seven unplanned intralesional (13.2%) 
resections. A biological barrier at the resection margin was 
present in nine patients (15%). A wide resection was not fea-
sible or not reconcilable with the patient’s wishes because of 
associated morbidity at the thoracolumbar spine (n=1, 1.7%) 
or pelvis (n=1, 1.7%). Two patients (3.3%) were admitted for 
further diagnostic assessment and treatment at our tertiary 
center after inadequate surgical resection at an external insti-
tution (“whoops” lesion). Additionally, under an assumption 
of enchondroma, two patients (3.3%) underwent an intral-
esional curettage and secondary resection was performed 
(“Biopsy sampling error” section). In one mesenchymal 
chondrosarcoma of the mandibula (1.7%) an adequate surgi-
cal resection could not be achieved and therefore the patient 
underwent adjuvant radiotherapy.
Prognostic factors for Dss
A total of 16 patients (23.5%) died of disease-related causes 
and one patient (1.5%) died of another cause. The DSS of the 
total 68 patients was 79.2±8.5% at 5 years and 75.5±6.4% 
at 10 years. DSS varied significantly among histological 
types: dedifferentiated types showed the worst survival 
rates (10±9.3% at 10 years) while low-grade tumors showed 
the best survival rates (93.8±4.0% at 10 years; P<0.001) 
( Figure 1, Table 3). Histological grade remained a significant 
risk factor in multivariate analysis and the HR for DSS was 
1.2 (95% CI: 0.73–2.00). Furthermore, metastatic disease at 
the time of diagnosis was identified as a risk factor with an 
HR for DSS of 7.95 (95% CI: 2.08–30.38).
A wide resection was associated with a better DSS of 
88±8.3% at 10 years compared with the DSS associated 
with an unplanned intralesional resection (37.5±17.1%). 
This factor did not remain significant after Bonferroni cor-
rection (Table 3). A complete list of the reviewed risk factors 
is highlighted in Table 3. Rare histological subtypes (n<2) 
were not illustrated.
Prognostic factors for lRFs
Local recurrence occurred in 12 patients (17.6%) and the 
median time to local recurrence was 1.8 years (range, 0.4–7.9 
years). The rate of LRFS was 82.2±7.8% at 5 years and 
76.9±7.8% at 10 years. In univariate analysis, a lower histo-
logical grade was associated with a better LRFS (86±10.5% 
at 10 years, P<0.001) (Table 4). In multivariate analysis, a 
higher histological grade remained an independent prognostic 
factor for poor LRFS (P<0.001) with an HR of 1.58 (95% CI: 
0.99–2.51) (Table 4). An intact biological barrier was associ-
ated with the most preferable LRFS of 89±10.5% at 10 years 
compared with that of an unplanned intralesional resection 
of 57.1±18.7% (Table 4, Figure 2). This trend showed no 
statistical significance after Bonferroni correction (Table 4). 
Further risk factors are shown in Table 4.
Intended intralesional curettage in low-grade appendicu-
lar chondrosarcoma was not included (n=7).
Discussion
To the best of our knowledge, this is the first study to examine 
the role of biopsy sampling errors and the impact of resection 
margin quality on DSS and LRFS in chondrosarcomas. The 
limitations of this study include its retrospective design and 
the relatively small sample size owing to the low incidence 
of this disease. The intra- and inter-observer reliability of 
histological grading could not be assessed because of the 
retrospective design and may potentially have influenced 
the reported outcomes. However, all pathological specimens 
were assessed by experienced pathologists, who specialize 
in sarcomas. Treatment protocols may have varied among 
the cohort as the study was conducted over a 15-year period. 
However, the applied diagnostic and therapeutic approaches 
remained largely unchanged.
Although the histological features of cartilaginous tumors 
have been described in detail, they remain a diagnostic chal-
lenge in terms of preoperative biopsies, and diagnosis relies 
on clinical and radiological findings.4–7 Biopsy sampling 
errors were relatively rare and did not affect DSS and LRFS Figure 1 Disease-specific survival according to histological grading.
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in our cohort. However, a secondary resection was required in 
two cases with a previously assumed low-grade lesion. This 
underlines the importance of the preoperative biopsy and its 
possible far-reaching consequences. The incidence of biopsy 
sampling errors in our cohort was smaller than that reported 
by Roitman et al, who reported biopsy sampling errors in 
up to 41% of cases.11 Furthermore, we did not reproduce 
findings of a higher incidence at the axial skeleton or pelvis 
or a correlation with tumor size. Because of considerable 
inter-observer variability in histological grading in carti-
laginous tumors, the role of preoperative biopsies remains 
controversial, especially in high-volume axial tumors, and 
should always be assessed in combination with clinical and 
radiological findings.4 This is most likely the reason that 
biopsy sampling errors were not an independent risk factor 
for DSS and LRFS, since therapeutic decisions are also based 
on clinical and radiological findings. However, an evaluation 
of the diagnostic value of a CT-guided biopsy is beyond the 
scope of this paper. The impact of such biopsies needs to be 
elucidated, especially in low-grade lesions, if an intended 
intralesional curettage is planned.
Table 3 Prognostic factors for disease-specific survival (DSS)
Univariate
5-year DSS
Univariate
10-year DSS
P-value Multivariate
HR (95% CI)
histological gradea
•	 low-grade
•	 high-grade
•	 Dedifferentiated
0.94
0.67
0.10
0.94
0.67
na
P<0.001 1.2
(0.73–2.00)
Metastatic disease at diagnosis
•	 no
•	 Yes
0.81
0.16
0.81
0.16
P<0.001 7.95
(2.08–30.38)
surgical marginb
•	 Wide (>10 mm)
•	 Marginal (1–10 mm)
•	 intralesional (0 mm)
•	 intact biological barrier
•	 no biological barrier
0.88
0.67
0.38
0.86
0.71
0.88
0.67
0.38
0.86
0.71
P=0.09
Tumor localization
•	 appendicular
•	 axial/Pelvis
0.77
0.71
0.77
0.71
P=1
sex
•	 Female
•	 Male
0.81
0.70
0.81
0.70
P=1
Biopsy sampling error
•	 Yes
•	 no
0.70
0.76
0.70
0.76
P=1
age (years) P=1
Tumor volume (cm3) P=1
Notes: ahistological subtypes with an incidence <2 were not included. bEnneking classification applied to 53 patients who underwent surgery (planned intralesional curettage 
not included [n=7]). P-values: Bonferroni corrected, (significant values marked bold).
Abbreviation: na, not applicable. 
The presence of a biological barrier was associated with 
the most favorable DSS and LRFS. The vast majority of the 
patients in our cohort could be treated using limb-sparing 
surgery. One single local recurrence occurred when a bio-
logical barrier was present at the closest resection margin. 
Neither histological grading in accordance with Enneking 
et al,24 nor the distance in mm were significant risk factors 
for LRFS or DSS in a univariate Cox proportional hazards 
model. The definition of an adequate resection margin is 
still a matter of debate and various classifications have been 
proposed.21,22,24,26 For example, the assessment of a circum-
ferential resection margin in mm has been suggested by 
Wittekind et al.26 However, no study has yet demonstrated 
the significance of an anatomical barrier at the closest margin 
for LRFS or DSS in chondrosarcoma of the bone.27–29 Our 
findings support the importance of the quality of resection 
(biological barriers, including fascia and the periosteum) 
rather than an absolute numeric value. This finding can aid 
orthopedic tumor surgeons in preoperative planning. The 
inclusion of an anatomical barrier at the closest resection 
margin should be aimed for, if possible. However, the ultimate 
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role of the distance to the closest resection margin could not 
be elucidated reliably in the current study. Uniform criteria 
with histopathological assessment of the distance in mm 
and the presence of biological barriers are necessary for 
the reproducibility of future research. Further large studies 
are needed to examine the role of quantitative vs qualitative 
criteria to assess resection margins.
Table 4 Prognostic factors for local recurrence-free survival (lRFs)
Univariate
5-year LFRS
Univariate
10-year LFRS
P-value Multivariate
HR /95% CI/ P-value
histological grade*
•	 low-grade
•	 high-grade
•	 Dedifferentiated
0.97
0.73
0.39
0.86
0.73
na
P<0.001 1.58
(0.99–2.51)
Metastatic disease at diagnosis
•	 no
•	 Yes
0.84
0.53
0.78
0.53
P=1
surgical margin**
•	 Wide (>10 mm)
•	 Marginal (1–10 mm)
•	 intralesional (0 mm)
•	 intact biological barrier
•	 no biological barrier
0.87
0.75
0.57
0.89
0.76
0.87
0.75
0.57
0.89
0.70
P=1
Tumor localization
•	 appendicular
•	 axial/Pelvis
0.81
0.81
0.76
0.81
P=1
gender 
•	 Female
•	 Male
0.86
0.79
0.75
0.79
P=1
Biopsy sampling error
•	 Yes
•	 no
0.89
0.81
0.89
0.74
P=1
age (years) P=1
Tumor volume (cm3) P=1
Notes: ahistological subtypes with an incidence <2 were not included. bEnneking classification was applied to 53 patients who underwent surgery (planned intralesional 
curettage not included [n=7]). P-values: Bonferroni corrected (significant values marked bold).
Abbreviation: na, not applicable. 
Histological grade is a significant prognostic risk factor 
for DSS and LRFS, with a worse outcome for dedifferentiated 
lesions and the best outcome for low-grade chondrosarcoma 
in our cohort. Metastatic disease at the time of diagnosis was 
the biggest risk factor for DSS with an HR of 7.95 (95% CI: 
2.08–30.38). These findings are in accordance with previ-
ously published studies.1,15,30,31 The overall DSS in the current 
study was slightly higher than that reported Giuffrida et al 
and Damron et al, who analyzed risk factors in the largest 
cohort studies to date, despite a higher rate of dedifferenti-
ated lesions in our cohort compared with Beauchamp et al 
(14.7%, n=10 vs 1.4%, n=40).30,31 The overall rate of LFRS 
was within the range of that reported in previously published 
cohort studies.30,31
Some of the previously described prognostic factors in 
chondrosarcoma, such as tumor volume, tumor localization 
or age, did not impact DSS or LRFS in our overall cohort, or 
in a subgroup analysis of exclusively localized conventional 
chondrosarcoma (low- and high-grade). This might have been 
caused by the relatively small sample size, as well as the rela-
tively high percentage of included dedifferentiated lesions.
Figure 2 local recurrence-free survival according to surgical margins.
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Conclusion
Even though histologic grading in chondrosarcoma is dif-
ficult, sampling errors in preoperative biopsies are relatively 
rare and do not affect outcomes. The presence of an ana-
tomical barrier has a higher impact on LRFS than the metric 
distance of the surgical margins. Moreover, we confirmed 
that histological grade and stage of disease are significant 
risk factors for DSS and LRFS in chondrosarcoma.
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